You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Infections
  5. Hepatitis

Elbasvir–grazoprevir for treating chronic hepatitis C

  • Technology appraisal guidance
  • Reference number: TA413
  • Published:  26 October 2016
  • Guidance
  • Tools and resources
  • Information for the public
  • History

On this page

  1. Expected publication
  2. Final appraisal determination
  3. Invitation to participate
  4. Draft scope documents

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 165 KB)

    Published:
    26 October 2016

Final appraisal determination

  • Final appraisal determination

  • Final appraisal determination document (PDF 302 KB)

    Published:
    09 September 2016
  • Committee papers (PDF 15.76 MB)

    Published:
    09 September 2016
  • Committee papers Committee meeting slides (PDF 480 KB)

    Published:
    09 September 2016

Invitation to participate

  • Final scope (PDF 170 KB)

    Published:
    25 February 2016
  • Final matrix (PDF 155 KB)

    Published:
    25 February 2016
  • NICE's response to comments on the draft scope and provisional matrix (PDF 384 KB)

    Published:
    25 February 2016
  • Equality impact assessment (Scoping) (PDF 122 KB)

    Published:
    29 February 2016

Draft scope documents

  • Draft scope (pre-referral) (PDF 179 KB)

    Published:
    04 February 2016
  • Provisional matrix (pre-referral) (PDF 155 KB)

    Published:
    04 February 2016
Back to top